Company profile for Arcutis Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and ...
Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2945 Townsgate Road, Suite 110 Westlake Village CA 91361
Telephone
Telephone
805-418-5006
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/17/3189050/0/en/FDA-Accepts-Supplemental-New-Drug-Application-for-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-the-Treatment-of-Plaque-Psoriasis-in-Children-Ages-2-to-5.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/13/3187274/0/en/Arcutis-Completes-Enrollment-in-INTEGUMENT-INFANT-Phase-2-Study-Evaluating-ZORYVE-roflumilast-Cream-0-05-in-Infants-with-Atopic-Dermatitis.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183944/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180240/0/en/Arcutis-Announces-Publication-of-Positive-Long-Term-Safety-and-Efficacy-Data-of-ZORYVE-roflumilast-Foam-0-3-in-Individuals-with-Seborrheic-Dermatitis-in-American-Journal-of-Clinica.html

GLOBENEWSWIRE
04 Nov 2025

https://www.fiercepharma.com/marketing/arcutis-taps-90210-star-power-spell-out-needs-skin-condition-patients

FIERCE PHARMA
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177307/0/en/Arcutis-Launches-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis-in-Children-Ages-2-to-5.html

GLOBENEWSWIRE
30 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty